Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Palace setting offers touch of magic to Olympic equestrian events
Recommended
What are the best neighborhoods in Raleigh, NC
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Travere Therapeutics Inc
(NQ:
TVTX
)
10.03
-0.16 (-1.57%)
Streaming Delayed Price
Updated: 10:49 AM EDT, Jul 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Travere Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
August 22, 2022
Via
Benzinga
Travere, CSL's Sparsentan Application Is Under European Review For Rare Kidney Disorder
August 22, 2022
Via
Benzinga
Travere Therapeutics Return On Capital Employed Overview
August 15, 2022
Via
Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
August 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Recap: Travere Therapeutics Q2 Earnings
August 04, 2022
Travere Therapeutics (NASDAQ:TVTX) reported its Q2 earnings results on Thursday, August 4, 2022. Here's what investors need to know about the announcement.
Via
Benzinga
Where Travere Therapeutics Stands With Analysts
July 26, 2022
Travere Therapeutics (NASDAQ:TVTX) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Analyst Ratings for Travere Therapeutics
May 17, 2022
Within the last quarter, Travere Therapeutics (NASDAQ:TVTX) has observed the following analyst ratings:
Via
Benzinga
FDA Says Travere's Sparsentan Data Not Sufficient For Accelerated Approval In One Indication
August 04, 2022
Travere Therapeutics Inc (NASDAQ: TVTX) completed its planned FDA Type A meeting for a potential submission for accelerated approval of sparsentan for focal segmental glomerulosclerosis (FSGS), a rare...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
August 03, 2022
Gainers
Via
Benzinga
4 Analysts Have This to Say About Travere Therapeutics
July 26, 2022
Over the past 3 months, 4 analysts have published their opinion on Travere Therapeutics (NASDAQ:TVTX) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
June 17, 2022
Gainers Travere Therapeutics (NASDAQ:TVTX) stock increased by 16.5% to $28.87 during Friday's after-market session. The market value of their outstanding shares is at $1.8 billion.
Via
Benzinga
HC Wainwright & Co. Maintains Buy Rating for Travere Therapeutics: Here's What You Need To Know
May 17, 2022
HC Wainwright & Co. has decided to maintain its Buy rating of Travere Therapeutics (NASDAQ:TVTX) and raise its price target from $45.00 to $46.00. Shares of Travere Therapeutics are trading up 8.5%...
Via
Benzinga
Travere Therapeutics Pops After Snagging Priority Review For A New Kidney Drug
May 16, 2022
The FDA will review Travere's drug by mid-November for a kidney disease.
Via
Investor's Business Daily
FDA Accepts Travere Therapeutics' NDA for Sparsentan with Priority Review
May 16, 2022
The U.S. Food and Drug Administration (FDA) has accepted Travere Therapeutics’ (NASDAQ: TVTX) New Drug Application (NDA) under Subpart H and granted Priority Review of sparsentan for the treatment of...
Via
Benzinga
Here's Why Travere Therapeutics Shares Are Rising Today
May 16, 2022
Travere Therapeutics Inc (NASDAQ: TVTX) shares are trading higher by 7.66% at $23.88 after the company received a priority review from the FDA for its treatment of IgA Nephropathy...
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
May 06, 2022
Gainers Kiromic BioPharma (NASDAQ:KRBP) stock increased by 12.6% to $0.58 during Friday's after-market session. The market value of their outstanding shares is at $8.9 million.
Via
Benzinga
Earnings Outlook For Retrophin
May 04, 2022
Retrophin (NASDAQ:TVTX) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Retrophin will...
Via
Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
May 02, 2022
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...
Via
Benzinga
The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data
April 21, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
April 10, 2022
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion.
Via
Benzinga
The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout
March 08, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022
March 31, 2022
Upgrades
Via
Benzinga
Travere Therapeutics: Q4 Earnings Insights
February 24, 2022
Travere Therapeutics (NASDAQ:TVTX) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:01 PM. Here's what investors need to know about the announcement....
Via
Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
February 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022
February 28, 2022
Upgrades According to DA Davidson, the prior rating for Envestnet Inc (NYSE:ENV) was changed from Neutral to Buy. In the fourth quarter, Envestnet showed an EPS of $0.50, compared...
Via
Benzinga
Travere Therapeutics's Earnings: A Preview
February 23, 2022
Travere Therapeutics (NASDAQ:TVTX) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement....
Via
Benzinga
Biotech Travere Therapeutics Stock Earns Relative Strength Rating Upgrade
February 14, 2022
Travere shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...
Via
Benzinga
Travere Posts Topline Data For Pegtibatinase In patients With Rare Metabolic Disorder
December 15, 2021
Travere Therapeutics Inc (NASDAQ: TVTX) reported topline results from the ongoing Phase 1/2 COMPOSE Study of pegtibatinase for classical homocystinuria (HCU)....
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
October 28, 2021
Gainers Bellerophon Therapeutics (NASDAQ:
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.